Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response
Vijayamahantesh Vijayamahantesh, Tapas Patra, Keith Meyer, Mohamad‐Gabriel Alameh, Erin K. Reagan, Drew Weissman, Ranjit Ray
Abstract
(includes an added potential N-linked glycosylation site and reduces CD81 binding activity)-mRNA-LNP candidate vaccine generates improved proinflammatory response and protective efficacy against a surrogate HCV vaccinia challenge model in mice. The results clearly suggested that HCV E2 exhibits immunoregulatory activity that inhibits induction of robust protective immune responses. Selection of engineered E2 antigen in an mRNA-LNP platform amenable to nucleic acid sequence alterations may open a novel approach for multigenotype HCV vaccine development.
Topics & Concepts
Proinflammatory cytokineBiologyImmune systemVirologyGlycoproteinImmunologyVirusHepatitis C virusInflammationMolecular biologyHepatitis C virus researchHepatitis B Virus StudiesLiver Disease Diagnosis and Treatment